VOLUME-4 | YEAR-2022
Case Report | Open Access | Diab Res Open Access. 2022 June 06;4(1):1-7
Effective Single Twymeeg Administration for Elderly Patient with Type 2 Diabetes (T2D), Arthralgia and Depression as Common Medical Problems
Masaki OKADA, Hiroshi BANDO*, Noboru IWATSUKI, Kazuki SAKAMOTO, Tomoya OGAWA
Pages: 1-7 | First Published: 2022 June 06 | DOI: 10.36502/2022/droa.6183
Background: Imeglimin (Twymeeg) has been effective for patients with type 2 diabetes (T2D).
Case Presentation: The patient is an 82-year-old female with T2D, arthralgia, and depression.
Results: She was given duloxetine hydrochloride (Cymbalta) and Twymeeg, leading to improved symptoms of low back pain (LBP), knee osteoarthritis, osteoporosis, depression, and possible mild cognitive impairment (MCI). HbA1c decreased from 8.8% to 7.1% for 4 months with a single administration of Twymeeg 2000mg/day.
Discussion: In recent clinical practice, elderly cases often tend to have simultaneously these problems, which are medical and social crucial problems. Twymeeg and Cymbalta may be indispensable agents for future practice.
Editorial | Open Access | Diab Res Open Access. 2023 Oct 03;4(1):8-11
Novel Nomenclature of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) for Future Hepatology
Hiroshi BandoiD*
Pages: 08-11 | First Published: 2023 Oct 03 | DOI: 10.36502/2023/droa.6184
Type 2 diabetes (T2D) has close relationships with nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), and others. The European Hepatology Society International Hepatology Conference (EASL-ILC) 2023 presented the announcement of novel nomenclatures for metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH). Furthermore, metabolic dysfunction-associated steatotic liver disease (MetALD) is used to describe those who consume greater amounts of alcohol, defined as more than 210g per week for males and more than 140g per week for females. MASLD may affect about one quarter of adults worldwide. Its criteria include the evidence of hepatic steatosis in three situations: obesity/overweight, T2DM, or the presence of metabolic dysfunction.